Roche reports positive haemophilia A data for Hemlibra

Roche has announced new clinical data offering further evidence of the benefits its drug Helimbra can offer for people with haemophilia A.

Positive interim results from the phase III HAVEN 4 study have shown that Hemlibra prophylaxis therapy, dosed once every four weeks, can improve bleed control for adults and adolescents with haemophilia A with and without inhibitors to factor VIII.

After a median of 17 weeks of treatment, Hemlibra prophylaxis delivered clinically meaningful control of bleeding, results that were consistent with previous studies of Hemlibra dosed once weekly or every two weeks.

These results add to the growing body of evidence showing how Hemlibra can be an effective treatment for people with haemophilia A regardless of their inhibitor status, while providing flexible administration options.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "Together with the findings from other phase III studies, these interim results support the potential for Hemlibra to be dosed at different schedules, allowing patients to choose the option that's right for them."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.